PIPELINES
PIPELINES

Founded in 2016 as a result of the technology and over 20 years of clinical practice and academic experience by Prof. Li Bin's team at Tongji Hospital of Tongji Medical College, Prof. Li conducted bench-to-bedside gene therapy studies, led to a series of China and international multi-center clinical trials that characterized the adeno-associated viral (AAV) vectors in inherited blindness. Leveraging the validated AAV platform, Neurophth has developed a rich pipeline of 10 products, aiming to serve patients with various retinal diseases including optic nerve damage-related diseases and vascular retinopathy.

PIPELINE DISEASE DISCOVERY PRE-CLINICAL IND PHASE 1/2  
NFS-01
Leber’s Hereditary
Optic Neuropathy
NFS-02
Leber’s Hereditary
Optic Neuropathy
NFS-04
Optic Neuropathy
(Glaucoma, etc.)
NFS-05
Autosomal Dominant
Optic Atrophy
NFS-07
Undisclosed
NFS-09
Undisclosed
NFS-10
Vascular Retinopathy
(wAMD, DME, etc.)
NFS-11
Undisclosed
NFS-12
Undisclosed
NFS-13
Undisclosed